AUG 10, 2026 · JOURNAL ARTICLE
A novel tetrahydrocurcumin derivative as a potential anti-colorectal cancer agent: studies on its design, synthesis, and in vitro and in vivo biological evaluation
Natural Products and Bioprospecting
Early-phase preclinical study demonstrating in vitro and xenograft efficacy of a novel compound; lacks human data, clinical outcomes, and independent replication needed to support therapeutic translation.
Reported
IC₅₀ (C5, HCT116 cells)2.66 ± 0.82 μM
IC₅₀ (H5, HCT116 cells)35.74 ± 1.40 μM
Potency fold-change (H5 vs C5)13-fold decline